These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 10794103)

  • 1. Membrane filtration for virus removal.
    Brandwein H; Aranha-Creado H
    Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of murine leukaemia virus from monoclonal antibody solution by a hydrophilic PVDF microporous membrane filter.
    Aranha-Creado H; Peterson J; Huang PY
    Biologicals; 1998 Jun; 26(2):167-72. PubMed ID: 9811524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of TSE agents by depth or membrane filtration from plasma products.
    Roberts PL; Evans D; Harris L
    Biologicals; 2010 Jan; 38(1):158-61. PubMed ID: 19854662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative viral titer reduction demonstrated by sequential challenge of a tangential flow membrane filtration system and a direct flow pleated filter cartridge.
    Aranha-Creado H; Fennington GJ
    PDA J Pharm Sci Technol; 1997; 51(5):208-12. PubMed ID: 9357307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus removal by filtration.
    Graf EG; Jander E; West A; Pora H; Aranha-Creado H
    Dev Biol Stand; 1999; 99():89-94. PubMed ID: 10404880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter.
    Oshima KH; Evans-Strickfaden T; Highsmith A
    Vox Sang; 1998; 75(3):181-8. PubMed ID: 9852404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Process scale considerations in evaluation studies and scale-up.
    Walter JK; Werz W; Berthold W
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Removal of human immunodeficiency virus by filtration with microporous regenerated cellulose membrane and by fractionation with polyethylene glycol].
    Hamamoto Y; Yamamoto N
    Nihon Rinsho; 1989 Jan; 47(1):161-7. PubMed ID: 2724562
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
    De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
    PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of anti-viral filters.
    Hughes B; Bradburne A; Sheppard A; Young D
    Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives.
    Berting A; Goerner W; Spruth M; Kistner O; Kreil TR
    J Med Virol; 2005 Apr; 75(4):603-7. PubMed ID: 15714487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
    Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
    Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
    Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
    PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bacteriological and technical testing of an 0.2-micrometer air-eliminating infusion filter (author's transl)].
    Beham A; Necek S
    Anaesthesist; 1981 Aug; 30(8):427-9. PubMed ID: 7283108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.